Difference between revisions of "Team:NUS Singapore"

Line 20: Line 20:
  
 
.citation {
 
.citation {
−
 
+
font-style: italic;
 
}
 
}
  
Line 40: Line 40:
 
<p>Recent advancements in engineered probiotics have enabled a host of novel medical therapeutics and diagnostics. One such example is scientists using engineered microbes to successfully target tumors in the gastrointestinal tract with minimal collateral damage and invasiveness [1, 2, 3, 4].Yet, despite these developments in engineered therapeutics, the risk of engineered microbes leaking into a non-designated environment remains an unresolved threat: a threat that could disrupt ecosystems and increase antibiotic resistance of natural bacteria. Therefore, critical to the feasibility of a functional engineered probiotic are control systems called killswitches that allow for spatial and temporal killing of the engineered probiotic once removed from its specific target site. However, the function of many existing killswitches is limited because they rely on: (1) Single input biosensors which decreases specificity [5]; (2) artificial amino acids which are difficult and unsuitable for implementation in the human body [6]; and (3) active control based on controlled expression of a toxin which in turn can lead to microbe survival upon mutagenesis of the killswitch [7, 8, 9].</p> <br><br>
 
<p>Recent advancements in engineered probiotics have enabled a host of novel medical therapeutics and diagnostics. One such example is scientists using engineered microbes to successfully target tumors in the gastrointestinal tract with minimal collateral damage and invasiveness [1, 2, 3, 4].Yet, despite these developments in engineered therapeutics, the risk of engineered microbes leaking into a non-designated environment remains an unresolved threat: a threat that could disrupt ecosystems and increase antibiotic resistance of natural bacteria. Therefore, critical to the feasibility of a functional engineered probiotic are control systems called killswitches that allow for spatial and temporal killing of the engineered probiotic once removed from its specific target site. However, the function of many existing killswitches is limited because they rely on: (1) Single input biosensors which decreases specificity [5]; (2) artificial amino acids which are difficult and unsuitable for implementation in the human body [6]; and (3) active control based on controlled expression of a toxin which in turn can lead to microbe survival upon mutagenesis of the killswitch [7, 8, 9].</p> <br><br>
  
−
<p>To improve current systems, Team NUSgem proposes a novel passive biocontainment system for the human gut with enhanced specificity, safeguard and with a newly added function of verification . Our cascaded dual-biosensor killswitch is configured to achieve an OR gate logic upon detection of a physical (temperature) and chemical (phosphate) input to enhance specificity. Upon detection of a wastewater environment outside of the human body, the system will inhibit the expression of anti-toxin IM2, thereby allowing the constitutively produced toxin- endonuclease E2, to destroy the engineered microbe. Our design purposefully places the E2 toxin gene in the probiotic’s genome to not only create plasmid addiction of an IM2 plasmid but also, serve to safeguard against mutation. Moreover, we use the bidirectional properties of the pTlpA36 promoter to express the verification of engineered microbe death which in turns allows for monitoring of the killswitch’s effectiveness which in turn can allow for a feedback-loop driven killswitch.<br>
+
<p>To improve current systems, Team NUSgem proposes a novel passive biocontainment system for the human gut with enhanced specificity, safeguard and with a newly added function of verification . Our cascaded dual-biosensor killswitch is configured to achieve an OR gate logic upon detection of a physical (temperature) and chemical (phosphate) input to enhance specificity. Upon detection of a wastewater environment outside of the human body, the system will inhibit the expression of anti-toxin IM2, thereby allowing the constitutively produced toxin- endonuclease E2, to destroy the engineered probiotic. Our design purposefully places the E2 toxin gene in the probiotic’s genome to not only create plasmid addiction of an IM2 plasmid but also, serve to safeguard against mutation. Moreover, we use the bidirectional properties of the pTlpA36 temperature sensitive promoter to express the verification of engineered probiotic death. Added verifcation provides monitoring of the killswitch's effectivness which in turn, has the potential to used as a stimulus for a feedback-loop driven killswitch. <br>
 
</p>  
 
</p>  
  
Line 47: Line 47:
  
 
<h5>Citations</h5>
 
<h5>Citations</h5>
−
<ol>
+
<ol class="citation">
 
<li>J. Claesen and M. Fischbach, “Synthetic Microbes As Drug Delivery Systems,” ACS Synthetic Biology, pp. 358-364, 2015.</li>
 
<li>J. Claesen and M. Fischbach, “Synthetic Microbes As Drug Delivery Systems,” ACS Synthetic Biology, pp. 358-364, 2015.</li>
 
<li>C. Pineo-Lambea, D. Ruano-Gallego and L. A. Fernandez, “Engineered bacteria as therapeutic agents,” Current Opinion in Biotechnology, vol. 35, pp. 94-102, 2015.</li>
 
<li>C. Pineo-Lambea, D. Ruano-Gallego and L. A. Fernandez, “Engineered bacteria as therapeutic agents,” Current Opinion in Biotechnology, vol. 35, pp. 94-102, 2015.</li>

Revision as of 07:52, 30 June 2017

Measurement Modelling Medal Check List
Team Member Attributions
Collaboration
Silver Up Gold Integrated
Overview Methodology Kill Switch for Probiotics Kill Switch for BeeT
Description Interlab Study Parts Experiment Documentation Improvement Demonstrate Safety Future Works
Home

Probiome

National University of Singapore

Project Abstract

Recent advancements in engineered probiotics have enabled a host of novel medical therapeutics and diagnostics. One such example is scientists using engineered microbes to successfully target tumors in the gastrointestinal tract with minimal collateral damage and invasiveness [1, 2, 3, 4].Yet, despite these developments in engineered therapeutics, the risk of engineered microbes leaking into a non-designated environment remains an unresolved threat: a threat that could disrupt ecosystems and increase antibiotic resistance of natural bacteria. Therefore, critical to the feasibility of a functional engineered probiotic are control systems called killswitches that allow for spatial and temporal killing of the engineered probiotic once removed from its specific target site. However, the function of many existing killswitches is limited because they rely on: (1) Single input biosensors which decreases specificity [5]; (2) artificial amino acids which are difficult and unsuitable for implementation in the human body [6]; and (3) active control based on controlled expression of a toxin which in turn can lead to microbe survival upon mutagenesis of the killswitch [7, 8, 9].



To improve current systems, Team NUSgem proposes a novel passive biocontainment system for the human gut with enhanced specificity, safeguard and with a newly added function of verification . Our cascaded dual-biosensor killswitch is configured to achieve an OR gate logic upon detection of a physical (temperature) and chemical (phosphate) input to enhance specificity. Upon detection of a wastewater environment outside of the human body, the system will inhibit the expression of anti-toxin IM2, thereby allowing the constitutively produced toxin- endonuclease E2, to destroy the engineered probiotic. Our design purposefully places the E2 toxin gene in the probiotic’s genome to not only create plasmid addiction of an IM2 plasmid but also, serve to safeguard against mutation. Moreover, we use the bidirectional properties of the pTlpA36 temperature sensitive promoter to express the verification of engineered probiotic death. Added verifcation provides monitoring of the killswitch's effectivness which in turn, has the potential to used as a stimulus for a feedback-loop driven killswitch.

Citations
  1. J. Claesen and M. Fischbach, “Synthetic Microbes As Drug Delivery Systems,” ACS Synthetic Biology, pp. 358-364, 2015.
  2. C. Pineo-Lambea, D. Ruano-Gallego and L. A. Fernandez, “Engineered bacteria as therapeutic agents,” Current Opinion in Biotechnology, vol. 35, pp. 94-102, 2015.
  3. T. Ford and P. Silver, “Synthetic biology expands chemical control of microorganisms,” Current Opinions in Biotechnology, no. 28, pp. 20-28, 2015.
  4. B. Sola-Oladokun, E. Culligan and R. Sleator, “Engineered Probiotics: Applications and Biological Containment,” The Annual Review of Food Science and Technology, pp. 356-359, 2017.
  5. D. I. Piraner, M. H. Abedi, B. A. Moser, A. Lee-Gosselin and M. G. Shapiro, “Tunable thermal bioswitches for in vivo control of microbial therapeutics,” Nature Chemical Biology, 2017.
  6. D. Mandell, M. Lajoie, M. Mee, R. Takeuchi, G. Kuznetsov, J. Norville, C. Gregg, B. Stoddard and G. Church, “Biocontainment of genetically modified organisms by synthetic protein design,” Nature, vol. 518, pp. 55-60, 2015.
  7. F. Stirling, L. Bitzan, J. Oliver, J. Way and P. Silver, “Rational Design of Evolutionarily Stable Microbial Kill Switches,” 21 04 2017. [Online]. Available: http://www.biorxiv.org/content/early/2017/04/21/129445.article-info.
  8. B. Torres, S. Jaenecke, K. Timmis, J. Garcia and E. Diaz, “A dual lethal system to enhance containment of recombinant micro-organisms,” Microbiology, vol. 149, pp. 3595-3601, 2003.
  9. C. T. Y. Chan, W. L. Jeong, D. E. Cameron, C. J. Bashor and J. J. Collins, “‘Deadman’ and ‘Passcode’ microbial kill switches,” Nature Chemical Biology, vol. 12, pp. 82-86, 2016.

Awards Criteria

Pages for awards